GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ — Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it is broadening the development focus…
Author: Ken Dropiewski
Bristol Myers Squibb Introduces “Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the U.S. annually Clinician-focused educational program, developed in partnership with Johnson & Johnson, highlights care for patients at high risk of thromboembolic events such as stroke, and the emerging potential […]
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio LATHAM, N.Y.–Feb. 3, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will […]
RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a […]
Lubrizol Launches Tolerathane™ Thermoplastic Polyurethane (TPU) for Implantable Medical Devices
CLEVELAND, OH – Lubrizol announces the launch of Tolerathane™ TPU, a new medical-grade material engineered to meet the evolving demands of implantable medical devices. Compared to other TPU materials, Tolerathane™ TPU offers unparalleled tolerance to harsh biological conditions while maintaining superior softness, mechanical resilience, and seamless integration into standard thermoplastics […]
Johnson & Johnson Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium
Accepted abstracts include a Late Breaker presentation of the OMNY-AF Pilot and real-world safety and efficiency data for the VARIPULSE Platform Introduction of the VARIPULSE Plus Platform reinforces Johnson & Johnson’s commitment to continued innovation Irvine, CA – February 3, 2026 – Johnson & Johnson is announcing new portfolio innovations in […]
SCAI Expert Opinion Explores ‘Wire-Free’ Angiography-Derived Physiology for Coronary Assessment
WASHINGTON—A new expert opinion from the Society for Cardiovascular Angiography & Interventions (SCAI) examines the evolving role of angiography-derived physiology (ADP), a wire-free method for coronary physiologic assessment that applies computational modeling or artificial intelligence (AI) to standard coronary angiographic images for the assessment and management of coronary artery disease. Published in JSCAI, “Angiography-Derived Physiology […]
Medtronic advances its innovation strategy with intent to acquire CathWorks
Deal demonstrates Medtronic’s commitment to expanding pipeline through strategic investments and targeted acquisitions Exercising option to acquire will bolster Medtronic’s interventional cardiology portfolio, expanding its leadership in transforming how cardiovascular disease is diagnosed and treated Medtronic’s intent to acquire follows a 2022 strategic partnership agreement with CathWorks GALWAY, Ireland, Feb. 3, 2026 /PRNewswire/ — Medtronic plc (NYSE:MDT), […]
SonoVascular Completes First Close of Series A Preferred Stock Financing
CHAPEL HILL, N.C., Feb. 3, 2026 /PRNewswire/ — SonoVascular, Inc., a clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy™ System, has completed the first close of its $6 million Series A preferred stock…
Volta Medical’s RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial Fibrillation
Volta Medical’s artificial intelligence (AI) solution demonstrated 83% freedom from atrial fibrillation (AF) at 12 months after a single procedure in patients with recurrent AF and isolated pulmonary veins following prior ablation MARSEILLE, France, Feb. 3, 2026 /PRNewswire/ — Volta…



